1 Zimmer L. Hillen U. Livingstone E. et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. In 2011, the Food and Drug Administration approved vemurafenib, a class 1 RAF inhibitor that is selective for BRAF, for use in unresectable or metastatic malignant melanoma. The BRAF V600E mutation is found in roughly 80%-90% of BRAF-mutated melanomas, and in about 50% of overall melanomas., 2 Göppner D. Müller J. Krüger S.